MedPath

Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)

Not Applicable
Recruiting
Conditions
Cancer
Registration Number
NCT06560398
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Brief Summary

The purpose of the study is to refine, finalize, implement, and evaluate a multi-level intervention aimed at increasing enrollment of Black and Hispanic patients to National Cancer Institute (NCI)-sponsored therapeutic clinic trials at Moffitt Cancer Center.

Detailed Description

A stratified cluster randomized design will be used to assess the impact of the Advancing Clinical Trials: Working through Outreach, Navigation, and Digitally Enabled Referral and Recruitment Strategies (ACT WONDER²S) multi-level intervention on increasing referral and enrollment to NCI-sponsored therapeutic clinical trials among Black and Hispanic patients. Geospatial analytics were used to identify clusters of census tracts within the Moffitt catchment area ("priority zones") with high Black and Hispanic populations for intervention deployment. Priority zones were then matched on population characteristics and randomized to receive the intervention (n=7) or to serve as controls (n=7).

External target populations within the Catchment Area Priority Zone (CAPZ) include community residents and community physicians, while internal target populations within Moffitt Cancer Center (Moffitt) include physicians, clinical research coordinators (CRCs), and patients. The outreach and education intervention components will be facilitated by community health educators (CHEs) targeting community residents (Clinical Trial Education module and CHE support through the ACT WONDER²S Phone-line/Email), community physicians (Continuing Medical Education sessions including implicit bias training), patients at Moffitt (CHE support) and cancer center physicians/CRCs (an implicit bias training). Digitally enabled decision support tools will be developed and deployed to the CHE's (a data-empowered interactive map for outreach planning \[Precision Engagement Tool\]), community physicians (Clinical Trial Newsletters), patients at Moffitt (a clinical trial decision aid \[CHOICES DA\]), and cancer center physicians/CRCs (a recruitment dashboard to monitor clinical trial accrual rates, a clinical trial portfolio profiler, and a tool to assess the impact of clinical trial inclusion/exclusion criteria on eligibility across patient populations defined by age, race, and ethnicity \[Eligibility Criteria Calculator\]). In addition, an online portal (called the Trial Connect Portal) will be developed to connect community-based referring physicians to information about MCC trials and to facilitate their communication with cancer center physicians and CRCs. The primary outcome, enrollment to clinical trials, will be measured by comparing the percentage of Moffitt patients enrolled on NCI-supported treatment trials who are Black or Hispanic between intervention priority zones and the control priority zones. The secondary outcome, referral to Moffitt, will be measured by comparing the percentage of patients referred to Moffitt who are Black or Hispanic between the intervention priority zones and the control priority zones.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
7649
Inclusion Criteria
  • Community residents: Community residents may engage with various intervention components deployed in the intervention priority zones.
  • Community Physicians: may engage with various intervention components deployed in the intervention priority zones if they 1) practice medicine in one of the geographic priority zones.
  • Cancer Center Physicians: may engage with various intervention components if they 1) practice medicine at Moffitt.
  • Clinical Research Coordinators (CRC): may engage with various intervention components if they 1) work as a CRC at Moffitt and 2) coordinate/pre-screen patients for at least 1 therapeutic clinical trial at Moffitt.
  • Cancer Center Patients: may engage with various intervention components if they have an address that maps to an intervention priority zone and 2) are newly registered patients or new existing patients (NEPs).
Exclusion Criteria
  • Community residents, Community Physicians, Cancer Center Physicians, Clinical Research Coordinators, and Moffitt patients who do not meet the inclusion criteria.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Enrollment of Black and Hispanic Patients to NCI-sponsored cancer treatment clinical trials2 years

Intervention impact on enrollment rates will be measured by comparing the percentage of Moffitt patients enrolled on NCI-supported treatment trials who are Black or Hispanic between intervention priority zones and the control priority zones.

Secondary Outcome Measures
NameTimeMethod
Referral of Black and Hispanic Patients to Moffitt Cancer Center2 Years

Intervention impact on referral rates will be measured by comparing the percentage of patients referred to Moffitt who are Black or Hispanic between the intervention priority zones and the control priority zones.

Cancer Center Physician2 years

The number of MCC physicians that used at least one of the CT digital tools.

Community physicians in the intervention CAPZ2 years

The number of physicians that attend a CME event.

Community residents in the intervention CAPZ2 years

The number of community residents that attend a CT educational session.

Cancer Center CRC2 years

The number of CRCs that used at least one of the CT digital tools.

Trial Locations

Locations (1)

Moffitt Cancer Center

🇺🇸

Tampa, Florida, United States

Moffitt Cancer Center
🇺🇸Tampa, Florida, United States
Rossybelle Amorrortu, MPH
Contact
813-745-4007
Rossybelle.Amorrortu@moffitt.org
Lindsay Fuzzell, PhD
Contact
Linsday.Fuzzell@moffitt.org
Susan Vadaparampil, PhD
Principal Investigator
Dana Rollison, PhD
Principal Investigator
Kea Turner, PhD
Sub Investigator
Kedar Kirtane, MD
Sub Investigator
Hatem Soliman, MD
Sub Investigator
Margaret Byrne, PhD
Sub Investigator
Cathy Meade, PhD
Sub Investigator
Clement Gwede, PhD
Sub Investigator
Steven Eschrich, PhD
Sub Investigator
Vivien Yin, PhD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.